• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用开源软件对非小细胞肺癌进行自动化程序性死亡配体1(PD-L1)评分

Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.

作者信息

Naso Julia R, Povshedna Tetiana, Wang Gang, Banyi Norbert, MacAulay Calum, Ionescu Diana N, Zhou Chen

机构信息

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Department of Pathology, BC Cancer, Vancouver, BC, Canada.

出版信息

Pathol Oncol Res. 2021 Mar 26;27:609717. doi: 10.3389/pore.2021.609717. eCollection 2021.

DOI:10.3389/pore.2021.609717
PMID:34257575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8262183/
Abstract

PD-L1 expression in non-small cell lung cancer (NSCLC) is predictive of response to immunotherapy, but scoring of PD-L1 immunohistochemistry shows considerable interobserver variability. Automated methods may allow more consistent and expedient PD-L1 scoring. We aimed to assess the technical concordance of PD-L1 scores produced using free open source QuPath software with the manual scores of three pathologists. A classifier for PD-L1 scoring was trained using 30 NSCLC image patches. A separate test set of 207 image patches from 69 NSCLC resection cases was used for comparison of automated and manual scores. Automated and average manual scores showed excellent correlation (concordance correlation coeffecient = 0.925), though automated scoring resulted in significantly more 1-49% scores than manual scoring ( = 0.012). At both 1% and 50% thresholds, automated scores showed a level of concordance with our 'gold standard' (the average of three pathologists' manual scores) similar to that of individual pathologists. Automated scoring showed high sensitivity (95%) but lower specificity (84%) at a 1% threshold, and excellent specificity (100%) but lower sensitivity (71%) at a 50% threshold. We conclude that our automated PD-L1 scoring system for NSCLC has an accuracy similar to that of individual pathologists. The detailed protocol we provide for free open source scoring software and our discussion of the limitations of this technology may facilitate more effective integration of automated scoring into clinical workflows.

摘要

非小细胞肺癌(NSCLC)中PD-L1的表达可预测免疫治疗的反应,但PD-L1免疫组化评分显示观察者间存在相当大的变异性。自动化方法可能会使PD-L1评分更一致、更便捷。我们旨在评估使用免费开源的QuPath软件得出的PD-L1评分与三位病理学家的手动评分之间的技术一致性。使用30个NSCLC图像切片训练了一个用于PD-L1评分的分类器。来自69例NSCLC切除病例的207个图像切片的单独测试集用于比较自动评分和手动评分。自动评分与平均手动评分显示出极好的相关性(一致性相关系数=0.925),尽管自动评分得出的1-49%评分显著多于手动评分(P=0.012)。在1%和50%的阈值下,自动评分与我们的“金标准”(三位病理学家手动评分的平均值)的一致性水平与个体病理学家相似。自动评分在1%阈值时显示出高敏感性(95%)但特异性较低(84%),在50%阈值时显示出极好的特异性(100%)但敏感性较低(71%)。我们得出结论,我们的NSCLC自动PD-L1评分系统的准确性与个体病理学家相似。我们为免费开源评分软件提供的详细方案以及我们对该技术局限性的讨论可能有助于将自动评分更有效地整合到临床工作流程中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/8fccb862143c/pore-27-609717-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/0bafee1859c9/pore-27-609717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/8c8339e1e115/pore-27-609717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/8fccb862143c/pore-27-609717-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/0bafee1859c9/pore-27-609717-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/8c8339e1e115/pore-27-609717-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/88c3/8262183/8fccb862143c/pore-27-609717-g003.jpg

相似文献

1
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.使用开源软件对非小细胞肺癌进行自动化程序性死亡配体1(PD-L1)评分
Pathol Oncol Res. 2021 Mar 26;27:609717. doi: 10.3389/pore.2021.609717. eCollection 2021.
2
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.使用自动化图像分析比较非小细胞肺癌中不同诊断 PD-L1 检测方法的连续测量值。
Mod Pathol. 2020 Mar;33(3):380-390. doi: 10.1038/s41379-019-0349-y. Epub 2019 Sep 16.
3
Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.评估用于肺癌程序性死亡配体-1(PD-L1)诊断检测评分的在线培训工具。
Diagn Pathol. 2020 Apr 17;15(1):37. doi: 10.1186/s13000-020-00953-9.
4
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.一项多机构研究,旨在评估免疫组织化学自动全片评分在非小细胞肺癌中评估程序性死亡配体1(PD-L1)表达的应用。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.
5
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.基于多阶段集成策略的非小细胞肺癌 PD-L1 表达自动肿瘤比例评分。
J Transl Med. 2021 Jun 7;19(1):249. doi: 10.1186/s12967-021-02898-z.
6
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.非小细胞肺癌活检的自动图像分析预测抗 PD-L1 治疗反应。
J Immunother Cancer. 2019 May 6;7(1):121. doi: 10.1186/s40425-019-0589-x.
7
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.深度半监督生成式学习在非小细胞肺癌组织穿刺活检肿瘤比例评分中的应用。
Sci Rep. 2018 Nov 26;8(1):17343. doi: 10.1038/s41598-018-35501-5.
8
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.一种经验证可用于分析非小细胞肺癌和头颈部鳞状细胞癌的程序性细胞死亡配体-1免疫组织化学检测方法的开发。
Diagn Pathol. 2016 Oct 8;11(1):95. doi: 10.1186/s13000-016-0545-8.
9
Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer.基于机器学习的图像分析算法可提高非小细胞肺癌 PD-L1 表达评分的病理学家间一致性。
J Clin Pathol. 2024 Jan 18;77(2):140-144. doi: 10.1136/jcp-2023-208978.
10
Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.PD-L1 免疫组织化学检测在非小细胞肺癌中的可比性:系统评价。
Histopathology. 2020 May;76(6):793-802. doi: 10.1111/his.14040. Epub 2020 Mar 24.

引用本文的文献

1
Artificial Intelligence (AI) for Programmed Death Ligand-1 (PD-L1) Immunohistochemical Assessment in Urothelial Carcinomas: "Teaching" Cell Differentiation to AI Systems.人工智能用于尿路上皮癌程序性死亡配体-1(PD-L1)免疫组化评估:向人工智能系统“传授”细胞分化
Life (Basel). 2025 May 22;15(6):839. doi: 10.3390/life15060839.
2
PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.中国非小细胞肺癌的PD-L1评分模型:现状、人工智能辅助解决方案及未来展望
Thorac Cancer. 2025 Apr;16(7):e70042. doi: 10.1111/1759-7714.70042.
3
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.

本文引用的文献

1
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.实验室自建与商业化PD-L1检测方法在非小细胞肺癌中的可比性
Ann Diagn Pathol. 2021 Feb;50:151590. doi: 10.1016/j.anndiagpath.2020.151590. Epub 2020 Aug 14.
2
Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization.通过图像分析和多重杂交提高PD-L1检测的诊断准确性。
Cancers (Basel). 2020 Apr 29;12(5):1114. doi: 10.3390/cancers12051114.
3
Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
数字病理学在非小细胞肺癌肿瘤百分比估计中的一致性。
Sci Rep. 2024 Oct 15;14(1):24163. doi: 10.1038/s41598-024-75175-w.
4
Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications.头颈部鳞状细胞癌中PD-L1表达的标准化数字图像分析揭示了样本内和样本间的异质性及其治疗意义。
Cancers (Basel). 2024 May 31;16(11):2103. doi: 10.3390/cancers16112103.
5
Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.免疫组化染色的程序性死亡配体 1 图像分析与传统人工评分方法的相关性。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241242635. doi: 10.1177/15330338241242635.
6
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.基于 PD-L1 表达的弱监督深度学习预测实体瘤的免疫治疗反应。
Cancer Res Commun. 2024 Jan 11;4(1):92-102. doi: 10.1158/2767-9764.CRC-23-0287.
7
Breaking Barriers: AI's Influence on Pathology and Oncology in Resource-Scarce Medical Systems.突破障碍:人工智能在资源匮乏医疗系统中对病理学和肿瘤学的影响
Cancers (Basel). 2023 Dec 2;15(23):5692. doi: 10.3390/cancers15235692.
8
The Role of Pathology-Based Methods in Qualitative and Quantitative Approaches to Cancer Immunotherapy.基于病理学的方法在癌症免疫治疗定性和定量方法中的作用。
Cancers (Basel). 2022 Aug 8;14(15):3833. doi: 10.3390/cancers14153833.
9
Prognostic value and computer image analysis of p53 in mantle cell lymphoma.p53 在套细胞淋巴瘤中的预后价值及计算机图像分析。
Ann Hematol. 2022 Oct;101(10):2271-2279. doi: 10.1007/s00277-022-04922-8. Epub 2022 Aug 3.
10
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.在头颈部鳞状细胞癌中使用人工智能进行程序性死亡受体1配体(PD-L1)自动评分
Cancers (Basel). 2021 Aug 31;13(17):4409. doi: 10.3390/cancers13174409.
PD-L1 免疫组织化学检测在非小细胞肺癌中的可比性:系统评价。
Histopathology. 2020 May;76(6):793-802. doi: 10.1111/his.14040. Epub 2020 Mar 24.
4
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.非小细胞肺癌中PD-L1生物标志物的观察者间可重复性:27位病理学家的多机构研究
J Pathol Transl Med. 2019 Nov;53(6):347-353. doi: 10.4132/jptm.2019.09.29. Epub 2019 Oct 28.
5
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.一项多机构研究,旨在评估免疫组织化学自动全片评分在非小细胞肺癌中评估程序性死亡配体1(PD-L1)表达的应用。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):263-269. doi: 10.1097/PAI.0000000000000737.
6
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.深度半监督生成式学习在非小细胞肺癌组织穿刺活检肿瘤比例评分中的应用。
Sci Rep. 2018 Nov 26;8(1):17343. doi: 10.1038/s41598-018-35501-5.
7
Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities.程序性死亡配体 1 反射诊断测试的批判性评价:当前标准和未来机遇。
J Thorac Oncol. 2019 Jan;14(1):45-53. doi: 10.1016/j.jtho.2018.09.025. Epub 2018 Oct 6.
8
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究:Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
9
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.PD-1 和 PD-L1 抑制剂作为癌症免疫疗法的一种形式的发展:注册试验的综合回顾和未来的考虑。
J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z.
10
Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer.肿瘤综合识别与自动评分最大限度减少病理学家的参与,并为乳腺癌的关键生物标志物提供新的见解。
Lab Invest. 2018 Jan;98(1):15-26. doi: 10.1038/labinvest.2017.131. Epub 2017 Dec 18.